文献速递泌尿男性生殖肿瘤

替沃扎尼对比索拉非尼治疗晚期肾细胞癌(TIVO-3):3期多中心随机对照开放标签研究

Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
PubMed 文献 · Lancet Oncol · 2019-12-03

TIVO-3研究在12个国家120家学术医院入组350例既往至少接受两种系统治疗(含VEGFR抑制剂)的转移性肾细胞癌患者,1:1随机接受替沃扎尼或索拉非尼。

要点

  • 三线或四线转移性肾细胞癌中,替沃扎尼较索拉非尼显著延长无进展生存期。
  • 替沃扎尼组最常见3/4级治疗相关不良事件为高血压(20% vs 14%)。
  • 两组严重治疗相关不良事件发生率相近(11% vs 10%),无治疗相关死亡。

核心结论

  • 替沃扎尼作为三线或四线治疗可改善转移性肾细胞癌患者的无进展生存期,且耐受性优于索拉非尼。

研究设计与样本

  • 开放标签、随机、对照、多中心3期试验,在12个国家120家学术医院进行。
  • 主要终点为意向治疗人群独立评审的无进展生存期,安全性分析纳入至少接受一剂研究治疗的患者。

主要发现

  • 最常见的3/4级治疗相关不良事件为高血压,替沃扎尼组35例(20%,173例中),索拉非尼组23例(14%,170例中)。
  • 严重治疗相关不良事件:替沃扎尼组19例(11%),索拉非尼组17例(10%);无治疗相关死亡报告。

关键数值与推荐

  • 入组标准:年龄>18岁、组织学或细胞学确诊的转移性肾细胞癌、至少两种既往系统治疗(含至少一种VEGFR抑制剂)、根据RECIST 1.1可测量病灶、ECOG体能状态0或1。
  • 排除既往接受替沃扎尼或索拉非尼治疗者。
  • 按IMDC风险类别和既往治疗类型分层,采用完全置换区组设计(区组大小4)随机分组。

临床怎么用

  • 对于既往接受过至少两种系统治疗(含VEGFR抑制剂)的转移性肾细胞癌患者,替沃扎尼可作为三线或四线治疗选择,尤其需关注高血压管理。

局限性

  • 开放标签设计,研究者和患者均未设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment for renal cell carcinoma has been revolutionised by inhibitors of VEGF receptor. Previous studies have suggested that treatment with a VEGF receptor (VEGFR) tyrosine kinase inhibitor might be effective in patients who had previous checkpoint inhibitor therapy. Therefore, TIVO-3 was designed to compare the efficacy and safety of tivozanib (a potent and selective VEGFR inhibitor) with those of sorafenib as third-line or fourth-line therapy in patients with metastatic renal cell carcinoma. METHODS: In this open-label, randomised, controlled trial done at 120 academic hospitals in 12 countries, we enrolled eligible patients older than 18 years with histologically or cytologically confirmed metastatic renal cell carcinoma and at least two previous systemic treatments (including at least one previous treatment with a VEGFR inhibitor), measurable disease according to the Response Evaluation Criteria in Solid Tumors version 1.1, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were excluded if they had received previous treatment with tivozanib or sorafenib. Patients were stratified by International Metastatic Renal Cell Carcinoma Database Consortium risk category and type of previous therapy and randomised (1:1) with a complete permuted block design (block size of four) to either tivozanib 1·5 mg orally once daily in 4-week cycles or sorafenib 400 mg orally twice daily continuously. Investigators and patients were not masked to treatment. The primary endpoint was progression-free survival by independent review in the intention-to-treat population. Safety analyses were done in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT02627963. FINDINGS: Between May 24, 2016, and Aug 14, 2017, 350 patients were randomly assigned to receive tivozanib (175 patients) or sorafenib (175 patients). Median follow-up was 19·0 months (IQR 15·0-23·4). Median progression-free survival was significantly longer with tivozanib (5·6 months, 95% CI 5·29-7·33) than with sorafenib (3·9 months, 3·71-5·55; hazard ratio 0·73, 95% CI 0·56-0·94; p=0·016). The most common grade 3 or 4 treatment-related adverse event was hypertension (35 [20%] of 173 patients treated with tivozanib and 23 [14%] of 170 patients treated with sorafenib). Serious treatment-related adverse events occurred in 19 (11%) patients with tivozanib and in 17 (10%) patients with sorafenib. No treatment-related deaths were reported. INTERPRETATION: Our study showed that tivozanib as third-line or fourth-line therapy improved progression-free survival and was better tolerated compared with sorafenib in patients with metastatic renal cell carcinoma. FUNDING: AVEO Oncology.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Rini BI, Pal SK, Escudier BJ, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2019. PMID: 31810797. doi:10.1016/S1470-2045(19)30735-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。